Drugs / therapeutic autologous lymphocytes
therapeutic autologous lymphocytes
also known as
autologous T-cells · autologous lymphocyte transfer (ALT) · autologous lymphocytes · Autologous peptide-specific activated lymphocytes · CIR T cells · PAL · re-activated T cells
Cell therapy targets CD19, PSCA via depletion
Trials 37 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003567 Background | May 1999 → Jan 2007 | cancer of unknown primary site, central nervous system neoplasm, lymphoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00603460 Comparator | Jan 2012 → Jan 2013 | ovarian cancer, primary peritoneal carcinoma | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00303836 Background | Nov 2005 → Jan 2007 | metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | therapeutic autologous lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00945269 ↗32 |
| Known as | autologous lymphocyte transfer (ALT) | “CMV-autologous lymphocyte transfer (ALT)” NCT00639639 ↗ |
| Known as | autologous lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00138229 ↗ |
| Known as | Autologous peptide-specific activated lymphocytes | “Autologous peptide-specific activated lymphocytes (PAL), previously harvested from the patient following vaccination on a different protocol, are expanded and reinfused intravenously” NCT00019357 ↗ |
| Known as | autologous T-cells | “All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109...” NCT01312376 ↗4“adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood autologous T-cells, and recombinant human interleukin-18 (SB-485232, IL-18) treatment” NCT02277392 ↗ “adoptive transfer of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells” NCT00603460 ↗ |
| Known as | CIR T cells | “The purpose of this study is to test the safety of infusing the study product CIR T cells.” NCT01355965 ↗ |
| Known as | PAL | “Autologous peptide-specific activated lymphocytes (PAL), previously harvested from the patient following vaccination on a different protocol, are expanded and reinfused intravenously” NCT00019357 ↗ |
| Known as | re-activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577588 ↗ |
| Action | Deplete | “Armed T cells aggregated and specifically killed HER2/neu(+) breast cancer cells.” PMID 11359672 ↗ Apr 2001 |
| Modality | Cell therapy | “the autologous lymphocytes are reinfused over at least 30 minutes” NCT00002589 ↗ |
| Route | Intravenous | “The activated T lymphocytes are infused IV over 1-6 hours” NCT00004022 ↗ |
| Target | CD19 | “CD3-positive cytotoxic T lymphocytes (CTLs) are isolated and genetically modified to express a CD19-specific chimeric immunoreceptor and the HyTK fusion protein, and are then...” NCT00182650 ↗ |